NEW YORK, March 12, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on XXII, ABEO, ADXS, and ADVM which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com revisits the Biotech space, which is a highly interdisciplinary field that combines biological sciences with engineering technologies to manipulate living organisms and biological systems to produce products that advances healthcare, medicine, agriculture, food, pharmaceuticals and environment control. Under assessment this morning are: 22nd Century Group Inc. (NYSE AMER: XXII), Abeona Therapeutics Inc. (NASDAQ: ABEO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM). All you have to do is sign up today for this free limited time offer by clicking the link below.
22nd Century Group
Clarence, New York headquartered 22nd Century Group Inc.'s stock finished last Friday's session 2.45% lower at $2.79. A total volume of 1.65 million shares was traded. The Company's shares have advanced 1.45% in the past month, 19.23% over the previous three months, and 196.81% over the past year. The stock is trading above its 200-day moving average by 15.55%. Additionally, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have a Relative Strength Index (RSI) of 51.27. Get the full research report on XXII for free by clicking below at: www.wallstequities.com/registration/?symbol=XXII
On Friday, shares in Dallas, Texas-based Abeona Therapeutics Inc. ended the session 1.32% higher at $15.30. The stock recorded a trading volume of 769,007 shares. The Company's shares have gained 3.38% in the previous three months and 191.43% over the past year. The stock is trading 2.21% above its 50-day moving average and 19.76% above its 200-day moving average. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 55.01.
On February 21st, 2018, Abeona Therapeutics announced that its senior management team will participate in the Barclays Global Healthcare Conference on March 13th, 2018, at 4:20 p.m. ET at Loews Miami Beach Hotel in Miami, Florida. Access the free research report on ABEO now by signing up at: www.wallstequities.com/registration/?symbol=ABEO
Princeton, New Jersey-based Advaxis Inc.'s shares jumped 8.37%, closing the session at $2.20. A total volume of 2.61 million shares was traded, which was above their three months average volume of 1.10 million shares. The stock is trading 17.84% below its 50-day moving average. Additionally, shares of Advaxis, which focuses on the discovery, development, and commercialization of Listeria monocytogenes technology-based immunotherapies in the US, have an RSI of 45.83.
On March 09th, 2018, Advaxis announced that it will release its financial results for the three months ended January 31st, 2018, on March 12th, 2018. Senior management will host a conference call and live audio webcast beginning at 4:30 p.m. ET that same day to review the results and provide a business update. The webcast may be accessed under the Events & Presentations page of the Company's investor relations website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ADXS at: www.wallstequities.com/registration/?symbol=ADXS
Last Friday at the close of trading, shares in Menlo Park, California headquartered Adverum Biotechnologies Inc. recorded a trading volume of 1.18 million shares. The stock ended the session 1.47% lower at $6.70. The Company's shares have surged 112.70% over the previous three months and 135.09% over the past year. The stock is trading above its 50-day and 200-day moving averages by 13.50% and 81.32%, respectively. Furthermore, shares of Adverum Biotechnologies, which engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease, have an RSI of 52.83.
On February 15th, 2018, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock, with a target price of $12 per share.
On February 26th, 2018, Adverum Biotechnologies announced that Amber Salzman, Ph.D., president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on March 12th, 2018, from 1:30 p.m. to 2:00 p.m. ET in Boston, Massachusetts. A live audio webcast of the presentation will be available on the Company's website. Aspiring Member, please take a moment to register below for your free research report on ADVM at: www.wallstequities.com/registration/?symbol=ADVM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities